



SDI Review Form 1.6

Journal Name:	Journal of Cancer and Tumor International
Manuscript Number:	Ms_JCTI_35247
Title of the Manuscript:	Prevalence of factors influencing recurrence and/or metastasis in dermatofibrosarcoma protuberans
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	The title was not addressed by the manuscript. There was no analysis on the factors that impact recurrence or metastasis. This is only a description of pt and tumor factors between DFSP and FS-DFSP	Thank you very much for reviewing our manuscript. The following are our responses: Larger DFSPs (probably greater than 2-5cm) are likely to have aggressive attributes such infiltrative growth pattern. Some DFSP are reported to start early in life and even in utero and grow indolently for a prolonged period, older age at diagnosis is probably; although not conclusively proven, associated with aggressive disease (high recurrence and distant metastasis). Similarly, the FS-DFSP variant is reported to have high propensity for recurrence and metastasis. Some studies also include gender and site of tumour as a risk factor for recurrence. We do not agree: The three issues have been studied and addressed in the manuscript.
<u>Minor</u> REVISION comments	- IRB approval should be stated - Median follow and range of follow up	- Noted. We had included the IRB Approval Number in the section dealing with Ethics i.e. last paragraph on Page 4 just before References (M130974). We have modified the manuscript and included the IRB Number in the Method Section. - Regarding the median and range of follow up. Please note that the study was an audit based on histopathology records. We did not perform a longitudinal study. Our interest on DFSP, including detailed record keeping and follow up only started after this study.
<u>Optional/General</u> comments		